Bupropion Dextromethorphan Dosing for Renal Impairment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with moderate renal impairment experiencing major depressive disorder face challenges with existing treatments due to increased risks of somnolence and dizziness, particularly when administering combinations of bupropion and dextromethorphan twice daily.
Innovation Solution
A method of treating major depressive disorder in patients with moderate renal impairment by administering a daily dose of 105 mg of bupropion hydrochloride and 45 mg of dextromethorphan hydrobromide, with the option to adjust dosing based on renal function and concomitant use of CYP2D6 inhibitors to minimize adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bupropion and dextromethorphan are administered twice daily to treat major depressive disorder, then therapeutic efficacy is improved, but the risk of somnolence and dizziness increases in patients with moderate renal impairment
Solution Approach 1:
The patent divides the dosing regimen into two distinct approaches based on renal function: once-daily dosing for patients with moderate renal impairment and twice-daily dosing for patients with normal renal function. This segmentation allows optimization of therapeutic efficacy while minimizing adverse effects in vulnerable patient populations.
Solution Approach 2:
The patent changes the dosing frequency parameter from the conventional twice-daily administration to once-daily administration specifically for patients with moderate renal impairment. This parameter change reduces peak plasma concentrations and cumulative exposure, thereby lowering the risk of somnolence and dizziness while maintaining antidepressant efficacy.
2Ease of operation
If standard dosing of bupropion and dextromethorphan is used in patients with moderate renal impairment, then treatment simplicity is maintained, but adverse effects increase
Solution Approach 1:
The patent implements a dynamic dosing strategy where the dosing frequency is adjusted based on the patient's renal function status. Once-daily dosing is recommended for patients with moderate renal impairment, while twice-daily dosing may be used for patients with normal renal function. This dynamic approach balances simplicity with safety.
Solution Approach 2:
The patent incorporates feedback from renal function assessment to guide dosing decisions. By evaluating creatinine clearance or estimated glomerular filtration rate, clinicians can determine whether once-daily or twice-daily dosing is appropriate, creating a feedback loop that optimizes both simplicity and safety.
3Reliability
If bupropion and dextromethorphan combination is administered to patients with moderate renal impairment, then treatment effectiveness is maintained, but the accumulation of drugs increases
Solution Approach 1:
The patent recommends once-daily dosing as a periodic action pattern for patients with moderate renal impairment. This extended dosing interval allows renal elimination to occur more completely between doses, reducing drug accumulation while maintaining treatment effectiveness through sustained therapeutic levels.
Solution Approach 2:
The patent changes the dosing frequency parameter from twice-daily to once-daily administration for patients with moderate renal impairment. This parameter change reduces the total number of doses and extends the elimination interval, thereby minimizing drug accumulation while preserving antidepressant efficacy.
Data Source
AI summary
This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.